The week's pick
Random Articles
Reseach Article
New Vistas in Drug Design Analysis: Computational Approach to Pharmacokinetics and Pharmacodynamics Tool Development
| International Journal of Computer Applications |
| Foundation of Computer Science (FCS), NY, USA |
| Volume 84 - Number 11 |
| Year of Publication: 2013 |
| Authors: Deepalakshmi. R, Jothi Venkateswaran C, Priya Shankar |
10.5120/14618-2928
|
Deepalakshmi. R, Jothi Venkateswaran C, Priya Shankar . New Vistas in Drug Design Analysis: Computational Approach to Pharmacokinetics and Pharmacodynamics Tool Development. International Journal of Computer Applications. 84, 11 ( December 2013), 7-14. DOI=10.5120/14618-2928
Abstract
The Pharmacokinetic/Pharmacodynamic (PK/PD) modeling associated simulation could as well be used as an 'applied science' tool to seek effective end results. The latest medication ensuring and enhancing safety, affordable cost and quicker results are greatly anticipated. The PK/PD modeling might be used from the run through all clinical phases of drug development. The best use of PK/PD modeling and simulation sometimes may result with unsuccessful compounds and study failures and at times a few studies might require registration. In order to demonstrate the potentiality of the PK/PD modeling in drug development, it has to be embraced by the business men and the restrictive agencies, and in addition to it, people have to be educated upon the subject. The Mechanism-based Pharmacokinetic-Pharmacodynamic (PK/PD) modeling is a popular computational method used for simulating the drug treatment of infectious diseases. It possesses the potential to reinforce our understanding of drug treatment outcomes, drug readying methods, and dosing regimens. A computational developed tool though expensive can address issues such as weak patient compliance and drug resisting power. The methodologies used in the previous PK/PD models limits the user approach as it needs computer literacy to operate the tool. An attempt is made to create a user friendly tool, the PK/PD which could be operated at ease by anyone and everyone.
References
- Dong, Jennifer Q, Chen, Bin, Gibbs Megan A, Emery, Maurice, John P. , Applications of Computer-Aided Pharmacokinetic and Pharmacodynamic Methods from Drug Discovery Through Registration, Volume 4, Number 1, pp. 54-66(13), Bentham Science Publishers (2008).
- Reisfeld B, Mayeno A, Lyons M, Yang R: Physiologically-based pharmacokinetic and pharmacodynamics modeling. In Computational Toxicology: Risk Assessment for Pharmaceutical and Environmental Chemicals. Edited by Ekins S, Wiley, pp 33, ( 2007).
- Lakshmi Kamath, Modeling Success in PK/PD Testing, 39(10):1954-60 (2011).
- Lake AD, Novak P, Fisher CD, Jackson JP, Hardwick RN, Billheimer, Klimecki, Cherrington NJ, Analysis of global absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease, pp. 464-469 (2011).
- Phillip J. Bergen, Jian Li and Roger L, Dosing of colistin, Department of Pharmacology and Toxicology, Tucson, AZ 85721, USA (2011).
- Czock D, Keller F, Mechanism-based pharmacokinetic–pharmacodynamics modeling of antimicrobial drug effects. J Pharmacokinetic Pharmacodynamic 34: pp. 727–751 (2007).
- Leon Aarons, Software for Population Pharmacokinetics and Pharmacodynamics, Volume 36, Issue 4, pp. 255-264 (1999).
- Robert J. Bauer, Serge Guzy, Chee Ng, A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamics models with examples, The AAPS Journal , Volume 9, Issue 1, pp. E60- E83 (2007).
- Beal SL, Sheiner LB, Methodology of population pharmacokinetics, Drug fate and metabolism: methods and techniques. New York: Marcel Dekker, 135–83. (1985).
- Racine-Poon A, Smith AFM. Population models, Statistical methodology in the pharmaceutical sciences. New York: Marcel Dekker, 139–62 (1990).
- Mallet A. A maximum likelihood estimation method for random coefficient regression models. Biometrika 73: 645–56. CrossRef (1986).
- Lindstrom MT, Bates DM. Nonlinear mixed effects models for repeated measures data. Biometrics; 46: 673–87. CrossRef (1990)
- Beal SL, Sheiner LB. NONMEM Users Guides (I–VIII). San Francisco: University of California NONMEM Project Group (1998).
- Yong Zhang, MeirongHuo, Jianping Zhou, ShaofeiXie, PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel, Computer Models and Programs in Biomedicine, Volume 99, Issue 3, pp. 306-314 (2010).
- Iris Rajman, PK/PD modeling and simulations: utility in drug development, Novartis Pharma AG, WSJ-210. 6. 29, CH-4056 Basel, Switzerland (2012).
- J. Y. Chien, Stuart Friedrich, Michael A, Heathman, Dinesh P. de Alwis, and Vikram Sinha Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation, AAPS J. September; 7(3): E544–E559 (2005).
- SimBiology model for PK/PD of anticancer drugs by Asawari Samant, Matlab Central (2011).
- Tan YM, Liao KH, Clewell r H J: Reverse dosimetry: interpreting trihalomethanes biomonitoring datausing physiologically based pharmacokinetic modeling. J Expo Sci Environ Epidemiol pp. 591-603, (2007).
- Marino DJ, Clewell HJ, Gentry PR, Covington TR, Hack CE, David RM, Morgott DA: Revised assessment of cancer risk to dichloromethane: Part I Bayesian PBPK and dose-response modeling in mice. Regul Toxicol Pharmacol, pp. 273-300, (2006)
- Lyons MA, Yang RSH, Mayeno AN, Reisfeld B: Computational toxicology of chloroform: reverse dosimetry using Bayesian inference, Markov chain Monte Carlo simulation, and human biomon-itoring data. Environmental Health Perspectives,pp. 116-124, (2008).
- Gelman A, Bois FY, Jiang J: Physiological pharmacokinetic analysis using population modeling and informative prior distributions. Journal of American Statistical Association, pp. 1400-1412, (1996).
- Tan C, Liao K, Clewell H: Physiologically Based Pharmacokinetic Modeling as a Tool to Interpret Human Biomonitoring Data. CIIT Activities, (2005).
- Liao KH, Tan YM, Clewell r H J: Development of a screening approach to interpret human biomonitor-ing data on volatile organic compounds: reverse dosimetry on biomonitoring data for trichloroethy-lene. Risk Anal, pp. 27-36, (2007).
- Selly, J. P. ,G. L. Amidon, W. H. Barr, L. Z. Benet, J. E. Carter, J. R. Robinson, V. P. Shah and A. Yacobi, "in Vitro and In Vivo Testing and Correlation for Oral Controlled/Modified Release Dosage Forms", Pharmaceutical Research, 7:975-982 (1990).
Index Terms
Keywords